Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet
Print
Malaz Abutarif, Ph.D.
Vice President
Daiichi Sankyo Inc
Poster(s):
029: Physiologically-based Pharmacokinetic Modeling of a Novel HER3-Targeted Antibody-Drug Conjugate, Patritumab Deruxtecan to Assess Pharmacokinetic Drug-Drug Interaction
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
075: Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
138: Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
